Lucence, a precision oncology company, was founded with the mission to bring clarity to cancer care through innovative diagnostics. The company specializes in developing ultrasensitive non-invasive liquid biopsy tests, which provide crucial information for the early detection and effective treatment of cancer. Lucence aims to redefine the future of early cancer detection by creating advanced blood-testing technologies that are both accurate and affordable, targeting a global market of healthcare providers and patients.
Notable figures affiliated with Lucence include its founder and key investors who have supported its growth. The company has achieved significant milestones, including the development and commercialization of its LiquidHALLMARK® multi-cancer screening test. Lucence's work has had a profound impact on the field of oncology, offering new hope for earlier cancer diagnosis and improved patient outcomes.
